These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3765 related articles for article (PubMed ID: 6845797)

  • 21. Immunologic mechanisms in malignant melanoma of the skin.
    Cochran AJ
    Trans Ophthalmol Soc U K (1962); 1977 Sep; 97(3):385-8. PubMed ID: 347641
    [No Abstract]   [Full Text] [Related]  

  • 22. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
    Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
    Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppressive effect of surgery evaluated by the multitest cell-mediated immunity system.
    Berti Riboli E; Terrizzi A; Arnulfo G; Bertoglio S
    Can J Surg; 1984 Jan; 27(1):60-3. PubMed ID: 6467104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunoreactivity in patients with surgically removed melanoma in the course of BCG vaccination (author's transl)].
    Lochman I; Kyselá T; Machálek J; Lochmanová A; Beska F
    Cesk Dermatol; 1980; 55(6):372-7. PubMed ID: 7460040
    [No Abstract]   [Full Text] [Related]  

  • 25. [Immunology of malignant melanoma].
    Bourgoin JJ
    Ann Inst Pasteur (Paris); 1972 Apr; 122(4):789-807. PubMed ID: 4559237
    [No Abstract]   [Full Text] [Related]  

  • 26. [Immunological conditions in patients with malignant melanoma of the skin].
    Kristensen E
    Ugeskr Laeger; 1976 Feb; 138(8):463-8. PubMed ID: 1258214
    [No Abstract]   [Full Text] [Related]  

  • 27. Some aspects of cell-mediated hypersensitivity in patients with melanoma.
    Moszkowska G; Jassem J; Kondrat W; Kopacz A; Goszczyńska E
    Arch Immunol Ther Exp (Warsz); 1980; 28(4):655-60. PubMed ID: 6970028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
    Kageshita T; Ishihara T; Campoli M; Ferrone S
    Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experimental induction of the delayed reaction as immunologica indicator (in dermatoses, tumors, immunosuppression)].
    Remy W; Stüttgen G
    Allerg Immunol (Leipz); 1972; 18(2):97-104. PubMed ID: 4266967
    [No Abstract]   [Full Text] [Related]  

  • 30. [Evaluation of cellular immunity in melanoma by means of a modified leukocyte migration inhibition test].
    Bowszyc J; Bowszyc J; Wojnerowicz-Grajewska M; Milanowski L
    Przegl Dermatol; 1980; 67(3):319-23. PubMed ID: 6968922
    [No Abstract]   [Full Text] [Related]  

  • 31. Recall antigen delayed-type hypersensitivity skin testing in melanoma and acute leukemia patients and their associates.
    Morris DL; Hersh EM; Hsi BP; Gutterman JU; Marshall MM; Mavligit GM
    Cancer Res; 1979 Jan; 39(1):219-26. PubMed ID: 761192
    [No Abstract]   [Full Text] [Related]  

  • 32. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
    Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
    Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell-mediated immunity against malignant melanoma in monozygous twins.
    Nagel GA; St Arneault G; Holland JF; Kirkpatrick D; Kirkpatrick R
    Cancer Res; 1970 Jun; 30(6):1828-32. PubMed ID: 5466283
    [No Abstract]   [Full Text] [Related]  

  • 34. Tumor-directed cellular immunity in malignant melanoma and its modification by surgical treatment.
    Cochran AJ; Thomas CE; Spilg WG; Grant RM; Cameron-Mowat DE; Mackie RM; Lindop G
    Yale J Biol Med; 1973 Dec; 46(5):650-4. PubMed ID: 4779137
    [No Abstract]   [Full Text] [Related]  

  • 35. Local delivery of poxvirus vaccines for melanoma.
    Hörig H; Kaufman HL
    Semin Cancer Biol; 2003 Dec; 13(6):417-22. PubMed ID: 15001160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy of advanced or metastatic melanoma.
    Cebon J; Gedye C; John T; Davis ID
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase.
    Piras F; Colombari R; Minerba L; Murtas D; Floris C; Maxia C; Corbu A; Perra MT; Sirigu P
    Cancer; 2005 Sep; 104(6):1246-54. PubMed ID: 16078259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging therapies for melanoma.
    Katipamula R; Markovic SN
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):553-60. PubMed ID: 18402522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blocking of a cellular immune reaction to malignant melanoma by immunoglobulin from tumor-bearing animals.
    Henderson WR; Fukuyama K; Epstein WL; Spitler LE
    J Reticuloendothel Soc; 1973 Feb; 13(2):155-60. PubMed ID: 4705738
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunotherapy for melanoma.
    Vaisrub S
    JAMA; 1973 Sep; 225(10):1242. PubMed ID: 4542440
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 189.